In unpredictable markets, resilience isn’t optional, it’s essential. This piece explores how economic and regulatory shocks test corporate strategies and why embedding agility and cross-functional coordination into CI frameworks empowers companies to weather turbulence and stay nimble.
Uncovering unpublished competitor pricing is challenging, but not impossible. This guide offers a practical, step-by-step approach to collect, validate, and benchmark unpublished pricing using secondary research, customer and competitor interviews, and ethical mystery shopping. Learn how to turn fragmented data into actionable pricing intelligence that sharpens your strategy and improves win rates.
Unlock the power of your customers’ voices to shape winning strategies. Learn how to systematically capture and analyze customer feedback, from surveys and interviews to social channels, and transform those insights into informed decisions. Discover ways to align product development, marketing, sales, and competitive positioning with real-world needs, so your organization isn’t guessing what matters, it’s responding with confidence.
What if you could anticipate competitor moves, market shifts and changing customer preferences, not react to them? Discover how integrating primary research into your Early Warning System empowers predictive intelligence, transforming reactive monitoring into proactive strategy.
In a high-stakes, fast-moving pharma landscape, the best competitive intelligence partners do more than deliver data, they drive strategy. This post outlines eight essential traits that set leading CI firms apart, based on real-world buyer insights and evolving industry demands.
At the Pharma CI Conference (Sept 25–26, 2024), leaders discussed how shifts like the IRA’s impact on drug pricing, AI in R&D, and shifting regulatory regimes are reshaping life sciences CI. Read this summary to grasp the conference’s breakout trends and strategic implications.
Pharmaceutical companies need more than public data to stay ahead. Learn how integrating pharmaceutical primary intelligence fills critical gaps and uncovers real-time competitive insights.
Competitive insight isn’t one-size-fits-all. We delve into multi‑pronged data collection, covering pricing, packaging, discounts, and bundling, to identify optimal tactics across segments and contexts. This post breaks down how to benchmark pricing strategies and create differentiated value propositions.
Through analysis of IO clinical trials (2018–2022), we reveal how top‑20 pharma concentrate on mAb trials globally, while smaller firms explore innovative modalities like BsAb and CAR‑T, and how China is emerging as an IO hub. These patterns offer strategic cues for reshaping your trial portfolio and R&D focus.
This first article, part of a three-post series, focusses on need for such a meeting and underlines the impact of accelerated approvals in the field of Oncology.
